Please assess the completion status of the following clinical trial:

Trial Title: Imaging Study for FdCyd and THU Cancer Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Enrolled in the National Institutes of Health (NIH) Phase II Clinical protocol evaluating 5-fluro-2'-deoxycytidine (FdCyd) with Tetrahydrouridine (THU) (09-C-0214) with target lesion measured as greater than or equal to 10mm with spiral computed tomography (CT) scan.~* Written, voluntary, informed consent of the patient must be obtained in compliance with institutional, state and federal guidelines~* For females: Negative serum pregnancy test OR post-menopausal for at least 2 years OR patient has had a hysterectomy~EXCLUSION CRITERIA:~* Participants with severe claustrophobia unresponsive to oral anxiolytics~* Subjects weighing \> 400 lbs (weight limit for scanner table), or unable to fit within the imaging gantry~* Known allergy to FdCyd~* The subject is unable to lie still for 75 minutes~* 5 Pregnant or lactating women. Pregnant women are excluded from this study because the effects of 18F-FdCyd in pregnancy are not known. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of 18F-FdCyd in the mother, breastfeeding should be discontinued if the mother receives 18F-FdCyd~* Participants with any co-existing medical or psychiatric condition that is likely to interfere with study procedures and/or results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1/Intravenous (IV) Tetrahydrouridine (THU) (Type: EXPERIMENTAL): \[F-18\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
- 2/Oral Tetrahydrouridine (THU) (Type: EXPERIMENTAL): \[F-18\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine

Based on this trial design, predict the completion outcome and termination type (if applicable).